Group 1 - The core transaction on September 23 involved a volume of 19.48 million shares and a transaction amount of 50.65 million yuan, with a transaction price of 2.60 yuan per share [2][3] - The buyer was China International Capital Corporation Wealth Securities Co., Ltd., Yantai Huanghai Road Securities Branch, and the seller was Huatai Securities Co., Ltd., Shaoxing Fushan Securities Branch [2] - In the last three months, the stock has seen a total of six block trades, amounting to a cumulative transaction value of 107 million yuan [3] Group 2 - On the same day, the closing price of Dongfang Ocean was 2.60 yuan, reflecting a decline of 2.62%, with a turnover rate of 3.38% and a total transaction amount of 138 million yuan [3] - The stock experienced a net outflow of 17.15 million yuan in main capital for the day, and over the past five days, it has cumulatively declined by 8.77% with a total capital outflow of 107 million yuan [3] - Shandong Dongfang Ocean Technology Co., Ltd. was established on December 19, 2001, with a registered capital of 1.9589465 billion yuan [3]

Core Viewpoint - Dongfang Ocean (002086.SZ) announced that its subsidiary, Mass Spectrometry Biotechnology Co., Ltd., has received registration approval from the Shandong Provincial Drug Administration for its self-developed fat-soluble vitamin testing kit, which utilizes liquid chromatography-tandem mass spectrometry. This product is now approved for market launch, enhancing the product line in the clinical testing field [1] Company Summary - The newly approved product will enrich the product offerings of Mass Spectrometry Biotechnology Co., Ltd. in the clinical testing sector [1] - Despite the product's approval, it is noted that the impact on the company's performance this year is minimal, indicating uncertainty regarding the future financial contributions of this product [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 质谱生物科技有限公司今年对公司的业绩影响较小，本次获批上市的脂 溶性维生素测定试剂盒（液相色谱—串联质谱法）的投产及对公司业绩的后续影 响具有不确定性，请广大投资者注意投资风险。 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 证券代码：002086 证券简称：东方海洋 公告编号：2025-052 山东东方海洋科技股份有限公司（以下简称"公司"）子公司质谱生物科技有 限公司自主研发的脂溶性维生素测定试剂盒（液相色谱—串联质谱法）于近日取 得了山东省药品监督管理局的注册批准，获得医疗器械注册证（体外诊断试剂）， 具体情况如下： 山东东方海洋科技股份有限公司 关于子公司取得医疗器械注册证的公告 同时，上述产品获证后还未投入生产，其实际销售情况受市场拓展力度及市 场实际需求等多重因素影响，目前 ...

每经AI快讯，东方海洋9月23日晚间发布公告称，山东东方海洋科技股份有限公司子公司质谱生物科技 有限公司自主研发的脂溶性维生素测定试剂盒于近日取得了山东省药品监督管理局的注册批准，获得医 疗器械注册证。产品名称为"脂溶性维生素测定试剂盒"。 每经头条（nbdtoutiao）——报价太低遭严防，投标企业还得"解释清楚"，一场国家组织的大型采购， 为何引发全行业关注 （记者 曾健辉） ...

Core Viewpoint - Dongfang Ocean (002086.SZ) announced that its subsidiary, Mass Spectrometry Biotechnology Co., Ltd., has received registration approval from the Shandong Provincial Drug Administration for its self-developed fat-soluble vitamin testing kit, which utilizes liquid chromatography-tandem mass spectrometry [1] Company Summary - The approved product will enhance the product line of Mass Spectrometry Biotechnology Co., Ltd. in the clinical testing field [1] - Despite the new product approval, the impact on the company's performance this year is expected to be minimal, indicating uncertainty regarding the future financial contributions of this product [1]

9月23日，东方海洋大宗交易成交1948.1万股，成交额5065.06万元，占当日总成交额的26.78%，成交价 2.6元，较市场收盘价2.6元持平。 ...

格隆汇9月19日丨东方海洋(002086.SZ)公布，公司近日获悉，国元基金于2025年9月17日通过集中竞价 方式减持公司股份1566.6万股，通过大宗交易方式减持公司股份381.4万股，于2025年9月19日通过集中 竞价方式减持公司股份10万股，共计减持1958万股，占公司总股本的1%（以下简称"本次减持"）。本 次减持后，国元基金持有公司股份156,735,727股，持股比例由9.00%变更为8.00%，变动触及1%的整数 倍。本次减持属于持股5%以上股东实施前期已披露的股份减持计划。 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-051 2 山东东方海洋科技股份有限公司 关于持股 5%以上股东减持股份触及 1%整数倍的公告 国元基金保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 深圳前海国元私募证券基金管理有限公司－国元价值精选一号私募证券投 资基金（以下简称"国元基金"）为持有山东东方海洋科技股份有限公司（以下简 称"公司"）5%以上股份的大股东，公司近日获悉，国元基金于 2025 年 9 月 17 日通过集中竞价方式减持公司股份 15,666,000 股，通过大宗交易方式减持公司股 份 3,814,000 股，于 2025 年 9 月 19 日通过集中竞价方式减持公司股份 100,000 股，共计减持 19,580,000 股，占公司总股本的 1%（以下简称"本次减持"）。本 次减持后，国元基金持有公司股份 156,735,727 股，持股比例由 9.00%变更为 8.00%，变动触及 1%的整数倍。本次减持属于持股 5%以上股东实施前期已披露 的股份减持计划。现 ...

Core Viewpoint - The company, Dongfang Ocean (002086.SZ), announced that its wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., has received registration approval from the Shandong Provincial Drug Administration for its self-developed fully automated chemiluminescent immunoassay analyzer, obtaining a medical device registration certificate [1] Group 1 - The automated chemiluminescent immunoassay analyzer is a significant development for the company [1] - The registration approval indicates compliance with regulatory standards, enhancing the company's credibility in the medical device market [1] - This achievement may open new market opportunities for the company in the healthcare sector [1]

东方海洋（002086）(002086.SZ)公告，公司全资子公司艾维可生物科技有限公司自主研发的全自动化 学发光免疫分析仪于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证。 ...